TrendsWide
Contact US
  • Home
  • Trending
  • Health
  • Life Style
  • NBA
  • Reviews
No Result
View All Result
TrendsWide
  • Home
  • Trending
  • Health
  • Life Style
  • NBA
  • Reviews
No Result
View All Result
TrendsWide
No Result
View All Result
Home Economie

Allogene Therapeutics tanks 45% on Friday as FDA halts cancer drug trial

by souhaib
October 8, 2021
in Economie
0
Allogene Therapeutics tanks 45% on Friday as FDA halts cancer drug trial
74
SHARES
1.2k
VIEWS
Share on FacebookShare on TwitterShare on Reddit
ADVERTISEMENT


Shares of Allogene Therapeutics Inc (NASDAQ: ALLO) tanked 45% to $13.35 on Friday after the U.S. FDA put a hold on its Cancer drug trial.

The sharp decline wiped millions off Allogene’s market cap, leaving the California-based firm with a valuation of $1.90 billion.  

Stifel downgrades the stock to ‘hold’


Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

Allogene said in a press release this morning that the U.S. drug regulator temporarily halted its clinical trial for allogenic Car T (AlloCAR T) therapy following a report of a chromosomal abnormality in a patient.

“Patient safety is our highest priority, and we are committed to working closely with the FDA to evaluate any potential clinical implications of this finding, and determine next steps for advancing ALLO-501A and our clinical programs.”

RBC Capital still rates ALLO at “outperform” but slashed its price target from $55 to $45. The announcement, however, made Stifel downgrade the stock from “buy” to “hold”.

The U.S. FDA review is ongoing

The study will remain suspended until the U.S. Food and Drug Administration reviews the single patient case. The press release read:

An investigation is underway to further characterise the observed abnormality, including any clinical relevance, evidence of clonal expansion, or potential relationship to gene editing.

The U.S. firm has tested its gene-edited AlloCAR T products on over 100 patients. The ALPHA trials, it believes, confirms ALLO-501A to hold a favourable clinical profile against large B-cell lymphoma.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,

eToro






10/10

67% of retail CFD accounts lose money



Source link

You might also like

‘momentum is continuing into 2022’

Astra Space stock closed down 20% on Monday: here’s why

Ripple, Dogecoin, Litecoin price forecast for February 2022

Share30Tweet19Share
Previous Post

World Egg Day.. Its most prominent benefits support heart health and reduce weight.. Infographic

Next Post

IoTeX CEO: ‘you own your own privacy’ 2021

souhaib

Recommended For You

‘momentum is continuing into 2022’

by souhaib
February 7, 2022
0
‘momentum is continuing into 2022’

Shares of Chegg Inc (NYSE: CHGG) are up 10% in extended trading on Monday after the student services company said it performed better-than-expected in Q4, despite COVID-19 uncertainty....

Read more

Astra Space stock closed down 20% on Monday: here’s why

by souhaib
February 7, 2022
0
Astra Space stock closed down 20% on Monday: here’s why

Read more

Ripple, Dogecoin, Litecoin price forecast for February 2022

by souhaib
February 7, 2022
0
Ripple, Dogecoin, Litecoin price forecast for February 2022

The cryptocurrency market is advancing this Monday, and this situation also supports the price of Ripple XRP/USD, Dogecoin DOGE/USD, and Litecoin LTC/USD. Bitcoin is trading above the $44,000...

Read more

Analyst: ‘Apple would be forced into it if Amazon goes after Peloton’

by souhaib
February 7, 2022
0
Analyst: ‘Apple would be forced into it if Amazon goes after Peloton’

Read more

Should I buy Uber shares in February 2022?

by souhaib
February 7, 2022
0
Should I buy Uber shares in February 2022?

Uber Technologies, Inc. (NYSE: UBER) will announce fourth-quarter earnings results this Wednesday, February 09, after the market closes. Uber shares have weakened more than 10% since the beginning...

Read more
Next Post
IoTeX CEO: ‘you own your own privacy’ 2021

IoTeX CEO: 'you own your own privacy' 2021

No Result
View All Result

Recent Posts

  • Ryan Gosling Responds To Those Who Say He’s ‘Too Old’ To Play Ken In The ‘Barbie’ Movie
  • Studies of bombshell Trump recording suggests prosecutors could have grounds to charge him beneath the Espionage Act
  • Insiders Load Up on These 2 Dividend Stocks With Impressive Yields of 8% or More
  • The Kremlin Slaps Absent Phone calls for Martial Legislation Just after Drone Assaults
  • John Forsyth, lacking Missouri ER health care provider, found dead in Arkansas

Browse by Category

  • Australia
  • Automotive
  • Business
  • Celebrity
  • Cryptocurrency
  • Deals
  • Economie
  • Education
  • Entertainment
  • Euro
  • Forex
  • Gaming
  • Health
  • Life Style
  • NBA
  • News
  • Politics
  • Reviews
  • Sports
  • Switzerland
  • Trending
  • U.S.
  • Uncategorized

Categories

  • Australia
  • Automotive
  • Business
  • Celebrity
  • Cryptocurrency
  • Deals
  • Economie
  • Education
  • Entertainment
  • Euro
  • Forex
  • Gaming
  • Health
  • Life Style
  • NBA
  • News
  • Politics
  • Reviews
  • Sports
  • Switzerland
  • Trending
  • U.S.
  • Uncategorized

Pages

  • Contact US
  • Newsletter
  • Privacy Policy
  • Terms & Conditions

© 2021 - TrendsWide

No Result
View All Result
  • Home
  • Contact US
  • Privacy Policy
  • Trending
  • U.S.
  • Economie
  • Deals
  • Reviews
  • Cryptocurrency
  • Health
  • Life Style
  • NBA

© 2021 - TrendsWide